![Jackie Papkoff](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Jackie Papkoff
Profile
Jackie Papkoff served as Chief Scientific Officer at CFD Therapeutics, Inc., Senior VP & Chief Scientific Officer-Microbiome at Assembly Biosciences, Inc., Senior Vice President-Research at Evelo Biosciences, Inc., and Vice President-Immunology Scientific Innovation at California Innovation Center.
Papkoff holds a doctorate degree from The Salk Institute for Biological Studies and the University of California San Diego, and an undergraduate degree from the University of California, Santa Cruz.
Former positions of Jackie Papkoff
Companies | Position | End |
---|---|---|
California Innovation Center | Corporate Officer/Principal | - |
ASSEMBLY BIOSCIENCES, INC. | Corporate Officer/Principal | - |
EVELO BIOSCIENCES, INC. | Chief Tech/Sci/R&D Officer | - |
CFD Therapeutics, Inc.
![]() CFD Therapeutics, Inc. Medical SpecialtiesHealth Technology CFD Therapeutics, Inc. (CFD), is being created to develop novel cancer therapeutics stemming from discoveries made previously by diaDexus. CFD will specifically focus on the development of therapeutic monoclonal antibodies directed against proprietary ovarian, pancreatic, breast, colon, prostate and lung cancer targets licensed from diaDexus. diaDexus, Inc. and San Francisco-based Biotechnology Value Fund L.P | Chief Tech/Sci/R&D Officer | - |
Training of Jackie Papkoff
The Salk Institute for Biological Studies | Doctorate Degree |
University of California San Diego | Doctorate Degree |
University of California, Santa Cruz | Undergraduate Degree |
Experiences
Positions held
Linked companies
Listed companies | 2 |
---|---|
ASSEMBLY BIOSCIENCES, INC. | Health Technology |
EVELO BIOSCIENCES, INC. | Health Technology |
Private companies | 2 |
---|---|
CFD Therapeutics, Inc.
![]() CFD Therapeutics, Inc. Medical SpecialtiesHealth Technology CFD Therapeutics, Inc. (CFD), is being created to develop novel cancer therapeutics stemming from discoveries made previously by diaDexus. CFD will specifically focus on the development of therapeutic monoclonal antibodies directed against proprietary ovarian, pancreatic, breast, colon, prostate and lung cancer targets licensed from diaDexus. diaDexus, Inc. and San Francisco-based Biotechnology Value Fund L.P | Health Technology |
California Innovation Center |
- Stock Market
- Insiders
- Jackie Papkoff